Abstracts tagged "OCD"

Abstract Number: 149 • 2020 Pediatric Rheumatology Symposium
Low C4 Copy Number of Total C4 Gene, C4B Gene and C4BL Gene in Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Agnieszka Kalinowski ¹, Justin Lee ², Haley Hedlin ², Reenal Pattini ², Hanna Ollila ², Emmanuel Mignot ¹, Douglas Levinson ², Susan Swedo ³, Tanya Murphy ⁴, Avis Chan ⁵, Margo Thienemann ¹, Alexander Urban ² and Jennifer Frankovich⁶, ¹Stanford University School of Medicine, Palo Alto, California, ²Stanford University, Palo Alto, California, ³National Institute of Mental Health, Bethesda, Maryland, ⁴University of South Florida, Tampa, Florida, ⁵Stanford University School of Medicine, Palo Alto, ⁶Stanford
Background/Purpose: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is characterized by sudden-onset OCD and additional neuropsychiatric symptoms. Imaging studies point to inflammation in the basal ganglia as…
Abstract Number: 150 • 2020 Pediatric Rheumatology Symposium
The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Jennifer Frankovich¹, Kirstin Anderson ², Gonzalo Montero-Martin ³, Avis Chan ⁴, Margo Thienemann ⁵, Bahare Farhadian ⁶, Theresa Willett ⁵, Elizabeth Mellins ⁷, Alicia Madden ⁵, Tanya Murphy ⁸, Susan Swedo ⁹, Marcelo Fernandez-Vina ³ and Jill Hollenbach ², ¹Stanford, ²University of California San Francisco, San Francisco, California, ³Stanford University, Palo Alto, California, ⁴Stanford University School of Medicine, Palo Alto, ⁵Stanford University School of Medicine, Palo Alto, California, ⁶Stanford Immune Behavioral Health Clinic and PANS Research Program at Lucile Packard Children's Hospital, Palo Alto, ⁷Stanford University, Stanford, ⁸University of South Florida, Tampa, Florida, ⁹National Institute of Mental Health, Bethesda, Maryland
Background/Purpose: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is characterized by abrupt onset of obsessive-compulsive disorder (OCD) and/or food restriction with other specified neuropsychiatric symptoms. Patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].